查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1870885

生技藥品外包市場按服務類型、治療領域、製程步驟、外包模式和最終用戶分類－2025-2032年全球預測

Biologics Outsourcing Market by Service Type, Therapeutic Area, Process Stage, Outsourcing Model, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，生技藥品外包市場規模將達到 594.5 億美元，複合年成長率為 12.68%。

主要市場統計數據
基準年 2024 228.7億美元
預計年份：2025年 258.1億美元
預測年份：2032年 594.5億美元
複合年成長率 (%) 12.68%

生技藥品外包的綜合策略框架，明確了其在縮短研發時間和降低複雜治療專案風險方面不斷演變的作用

生技藥品外包已成為企業加速研發進程、管理資本投資和取得專業能力的關鍵策略手段。過去十年，治療複雜性的不斷增加和新興複雜治療領域的出現，凸顯了外部合作夥伴的重要性，使外包從一種成本控制措施轉變為研發和商業化策略的核心組成部分。因此，研發商和生產商都在重新評估其夥伴關係，以確保產能、降低技術風險，並充分利用分析、填充和包裝流程以及上游和下游生產等領域的專業知識。

本文從多方面概述了正在重塑生技藥品外包價值鏈的技術創新、監管演變和商業性結構調整。

生技藥品外包格局正經歷著由技術、監管和商業性因素共同驅動的多面向變革。一次性技術和模組化設施設計的創新實現了快速週轉和靈活的產能部署，而先進的分析技術和數位化平台則有助於更深入地了解製程並加速技術轉移。同時，細胞和基因療法的興起催生了對專業載體生產、封閉式系統製程和客製化分析檢測的需求，從而重塑了供應商的能力和夥伴關係模式。

對近期美國關稅調整對生技藥品外包供應鏈經濟、生產力計畫和風險緩解策略的影響進行實證評估

2025年實施的關稅調整和貿易措施的累積影響，為生技藥品供應鏈帶來了新的考量因素，進而影響採購、資本規劃和區域籌資策略。具體而言，關稅的提高和進口組件分類範圍的擴大，導致一次性組件、層析法介質、專用過濾設備和分析儀器等關鍵材料的到岸成本上升。因此，製造商和服務供應商被迫重新評估供應商合約和總擁有成本（TCO），以維持利潤率和專案進度。

詳細的細分分析，將服務類型、治療領域、流程階段、外包模式和最終用戶優先順序映射到策略能力要求。

對生技藥品外包市場進行細分，有助於供應商和買家更了解其策略重點所在。按服務類型分類，分析服務、研發活動、填充和包裝流程以及生產製造構成獨特的價值流，每條價值流都有其自身的風險狀況和基礎設施需求。在生產製造流程中，下游和上游流程所需的技能和資本密集度各不相同。下游流程著重於層析法和過濾技術，對分析精度和耗材的持續供應要求很高。而上游流程則分為可實現快速切換的一次性系統和耐用且高生產率的不銹鋼平台。

整合區域情報，比較美洲、歐洲、中東、非洲和亞太地區的需求、製造能力、監管立場和投資趨勢。

區域趨勢對醫療服務能力、監管協調和投資流動有顯著影響。在美洲，生物技術創新高度集中，擁有健全的創業融資生態系統和完善的監管管道，因此對早期研發服務和商業化生產規模化都提出了強勁的需求。該地區受益於密集的專業醫療服務提供者網路、經驗豐富的監管審查人員以及接近性大規模患者群體的地理優勢，這些因素共同促進了項目的快速推進和務實的供應鏈協調。

已驗證的企業策略表明，領先的供應商如何最佳化產能、專業知識和數位化投資夥伴關係模式，從而在生技藥品外包領域建立優勢。

為了抓住新的機遇，生技藥品外包生態系統中的主要企業正在尋求差異化策略，以平衡產能擴張、技術專長和商業性夥伴關係。一些供應商專注於垂直整合，建構涵蓋分析開發、商業填充和包裝的全流程能力，提供端到端解決方案，從而減少交接環節，加快產品上市速度。另一些供應商則專注於病毒載體生產、高效能分析和連續下游加工等細分領域，為高複雜性專案提供深厚的專業知識和檢驗的製程，從而發揮優勢。

經營團隊應採取切實可行的優先行動，加強供應鏈，加速技術轉讓，並投資於能帶來可衡量的韌性和競爭優勢的能力。

產業領導者應採取一系列切實可行的積極措施，以增強競爭力和營運韌性。首先，詳細梳理供應鏈，識別單點故障、關稅風險和關鍵前置作業時間依賴關係，然後實施分階段的風險緩解計劃，該計劃應結合戰略庫存、供應商多元化和替代零件認證流程。其次，優先投資模組化和一次性技術，因為這些技術的靈活性能夠帶來可衡量的效益，同時保留部分不銹鋼製造能力，以實現大量、低成本的生產。

透明的混合方法研究途徑整合了第一手訪談、第二手資料、細分市場分析和情境分析，以得出可操作的見解。

本研究採用混合方法，確保研究結果的穩健性和實用性。主要研究包括對研發和製造機構的高階主管和技術負責人進行結構化訪談，並輔以與監管專家和供應鏈專家的諮詢，以檢驗假設並了解實際決策方法。這些主要資訊與從科學文獻、監管指導文件、行業白皮書和檢驗的公開資訊中提取的有針對性的二手研究進行三角驗證，從而構建了一個全面的證據基礎。

一份簡潔、全面的分析報告，強調了買方和供應商在能力、管治和投資方面保持一致以實現生技藥品永續開發的戰略必要性。

生技藥品外包的發展軌跡反映出該產業正處於戰略轉折點。技術創新、不斷變化的監管環境以及供應鏈重組正在共同提高合作夥伴選擇和專案執行的標準。那些積極重組籌資策略、投資特定能力並建立數據驅動決策框架的組織，將更有能力將科學進步轉化為可靠且可擴展的治療領域。同時，貿易政策趨勢和區域投資轉移凸顯了建構敏捷供應鏈結構和進行充分情境規劃的必要性。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 專注於mRNA疫苗生產的CDMO公司迅速擴大產能，以滿足全球疫苗生產需求。
  • 提高一次性反應器技術的應用，以加快生物加工的靈活性和效率。
  • 生技公司與CDMO在先進基因治療開發平臺的策略合作
  • 整合數位化品管系統可確保即時合規性和流程透明度。
  • 增加對用於個人化細胞和基因治療產品的彈性生產線的投資
  • 專注於採用永續外包方式，以減少生技藥品生產供應鏈中的碳足跡
  • 區域近岸外包策略日益盛行，旨在緩解供應鏈中斷和地緣政治風險。
  • 在生技藥品製程開發中應用人工智慧和機器學習進行最佳化

第6章美國關稅的累積影響，2025年

第7章 人工智慧的累積影響，2025年

第8章生技藥品外包市場（按服務類型分類）

  • 分析服務
  • 發展
  • 填充和精加工
  • 製造業
    • 下游工藝
      • 層析法
      • 濾
    • 上游工藝
      • 一次使用
      • 防鏽的

第9章生技藥品外包市場（依治療領域分類）

  • 細胞療法
    • 同種異體移植
    • 自體
  • 基因治療
    • 非病毒性
    • 病毒載體
  • 單株抗體
  • 疫苗
    • 預防
      • 細菌
      • 病毒
    • 治療

第10章生技藥品外包市場（依製程階段分類）

  • 臨床
    • 第一階段
    • 第二階段
    • 第三階段
  • 商業的
  • 研究

第11章生技藥品外包市場－以外包模式分類

  • CDMO
  • CMO
  • CRO

第12章生技藥品外包市場（依最終用戶分類）

  • 生技公司
  • 製藥公司
  • 研究所

第13章生技藥品外包市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章生技藥品外包市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國生技藥品外包市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Thermo Fisher Scientific Inc.
    • Catalent, Inc.
    • Lonza Group AG
    • Samsung Biologics Co., Ltd.
    • Boehringer Ingelheim International GmbH
    • Fujifilm Diosynth BIoTechnologies UK Ltd
    • AGC Biologics Inc.
    • WuXi Biologics（Cayman）Inc.
    • Recipharm AB
    • Vetter Pharma-Fertigung GmbH & Co. KG
Product Code: MRR-1A1A064C0467

The Biologics Outsourcing Market is projected to grow by USD 59.45 billion at a CAGR of 12.68% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 22.87 billion
Estimated Year [2025] USD 25.81 billion
Forecast Year [2032] USD 59.45 billion
CAGR (%) 12.68%

Comprehensive strategic framing of biologics outsourcing that defines its evolving role in accelerating development timelines and de-risking complex therapeutic programs

Biologics outsourcing has become a strategic fulcrum for organizations seeking to accelerate development timelines, manage capital investment, and access specialized capabilities. Over the past decade, increasing therapeutic complexity and the emergence of advanced modalities have elevated the role of external partners, transforming outsourcing from a cost-management tactic into a core element of R&D and commercialization strategy. As a result, developers and manufacturers alike are recalibrating their partnerships to secure capacity, mitigate technical risk, and leverage expertise in areas such as analytics, fill-finish operations, and both upstream and downstream manufacturing.

This introduction situates outsourcing within a broader ecosystem shaped by technological innovation, evolving regulatory expectations, and shifting supply chain dynamics. Companies are balancing the need for agility with the imperative for quality and regulatory compliance, prompting a proliferation of specialized service providers and modular manufacturing approaches. In turn, buyers are increasingly selective, seeking partners who offer not only technical proficiency but also transparent risk management, traceability, and integrated digital capabilities. Consequently, outsourcing decisions now hinge on strategic alignment, long-term capacity planning, and the ability of partners to co-develop solutions that advance program timelines while protecting product integrity.

Moving forward, stakeholders must view outsourcing through a dual lens: as an operational necessity and as a strategic lever for competitive differentiation. Those who successfully integrate external expertise into tightly governed development and manufacturing pathways will be better positioned to capitalize on emerging opportunities across diverse therapeutic areas and process stages.

A multidimensional overview of technological advancements, regulatory evolution, and commercial realignments that are reshaping biologics outsourcing value chains

The biologics outsourcing landscape is undergoing a multipronged transformation driven by converging technological, regulatory, and commercial forces. Innovations in single-use technologies and modular facility design are enabling faster turnarounds and flexible capacity deployments, while advanced analytics and digital platforms are improving process understanding and accelerating tech transfer. Simultaneously, the rise of cell and gene therapies has created demand for specialized vector manufacturing, closed-system processing, and bespoke analytical testing, reshaping vendor capabilities and partnership models.

Regulatory frameworks are also evolving to accommodate novel modalities, prompting providers to invest in compliance expertise and documentation practices that streamline approvals. At the same time, commercial pressures, including the need for rapid scale-up, cost containment, and supply continuity, are incentivizing strategic consolidation and collaborations that combine development, clinical manufacturing, and commercial-scale capacities under integrated service models. These shifts are accompanied by a heightened emphasis on supply chain resilience, environmental sustainability, and workforce development, all of which influence sourcing decisions and capital allocation.

Consequently, market participants are redefining value propositions: providers that offer end-to-end solutions, demonstrate robust quality systems, and can adapt capacity to fluctuating demand are gaining advantage. Buyers are increasingly evaluating partners on the basis of technical depth, regulatory track record, and the ability to co-invest in process optimization and lifecycle support, making long-term strategic alignment a primary differentiator in a rapidly changing landscape.

An evidence-based assessment of how recent United States tariff adjustments have reshaped supply chain economics, capacity planning, and mitigation strategies across biologics outsourcing

The cumulative impact of tariff policy adjustments and trade measures in the United States in 2025 introduced new considerations for biologics supply chains, influencing procurement, capital planning, and regional sourcing strategies. In practical terms, increased duties and broader classification of imported components have elevated the landed cost of critical inputs such as single-use assemblies, chromatography media, specialized filtration equipment, and analytical instruments. As a result, manufacturers and service providers must reassess supplier contracts and total cost of ownership calculations to preserve margins and program timelines.

In response, stakeholders are pursuing a range of mitigation strategies. Some organizations are accelerating diversification of supplier bases to reduce exposure to tariff-affected trade corridors, while others are exploring local production or nearshoring options to stabilize input costs and shorten supply lead times. These adaptations often require upfront capital and operational adjustments, including qualification of alternative components, validation of new supply partners, and potential rework of manufacturing processes to ensure equivalence. Moreover, procurement teams are intensifying engagement with customs and trade specialists to optimize tariff classifications, leverage duty drawback mechanisms where applicable, and navigate regulatory compliance.

Beyond direct cost implications, tariff-driven shifts exert secondary effects on capacity planning and strategic partnerships. Providers facing increased import costs may delay or restructure expansion plans, impacting available capacity for clients. Conversely, incentives to localize production have catalyzed investments in regional manufacturing hubs, altering competitive dynamics. Ultimately, the interplay between trade policy and biologics outsourcing underscores the importance of scenario planning and agile supply chain design as essential components of commercial resilience.

In-depth segmentation analysis that maps service types, therapeutic modalities, process stages, outsourcing models, and end-user priorities to strategic capability requirements

A segmented view of the biologics outsourcing landscape clarifies where providers and buyers must concentrate strategic effort. When services are considered by type, analytical services, development activities, fill-finish operations, and manufacturing represent distinct value streams with different risk profiles and infrastructure needs. Within manufacturing, downstream and upstream activities require divergent skill sets and capital intensity; downstream processes focus on chromatography and filtration capabilities that demand high analytical rigor and consumable supply continuity, while upstream processes bifurcate between single-use systems that enable rapid changeover and stainless steel platforms that deliver durable, high-volume performance.

Therapeutic area segmentation further refines capability requirements. Cell therapy and gene therapy programs necessitate specialized handling, cold chain logistics, and vector production, with cell therapy split across allogeneic and autologous approaches that carry contrasting supply chain models and patient-specific complexities. Gene therapy distinctions between non-viral and viral vector strategies drive different manufacturing and analytical burdens. Monoclonal antibodies remain a foundational category demanding robust upstream and downstream scale-up expertise, while vaccines, both prophylactic and therapeutic, require antigen-specific manufacturing and regulatory approaches; prophylactic vaccines themselves span bacterial and viral indications, each with unique process considerations.

Process stage segmentation emphasizes that development, clinical, and commercial phases call for tailored outsourcing solutions. Clinical-stage work must accommodate Phase I through Phase III variability in scale and regulatory oversight, whereas commercial operations prioritize repeatability, cost efficiency, and supply security. Outsourcing models vary accordingly, with CDMOs, CMOs, and CROs offering differentiated scopes of service and capacity models. End users-biotech companies, pharmaceutical companies, and research institutes-approach outsourcing with distinct commercial and governance imperatives, shaping contract structures, risk allocation, and partnership duration expectations.

A regional intelligence synthesis that contrasts demand, manufacturing capacity, regulatory posture, and investment trends across the Americas, EMEA, and Asia-Pacific

Regional dynamics exert a powerful influence on provider capabilities, regulatory alignment, and investment flows. In the Americas, concentration of biotech innovation, robust venture funding ecosystems, and established regulatory pathways create strong demand for both early-stage development services and commercial manufacturing scale-up. This region benefits from a dense network of specialized providers, experienced regulatory reviewers, and proximity to large patient populations, which together facilitate faster program advancement and pragmatic supply chain coordination.

Europe, the Middle East and Africa exhibit a complex mix of advanced manufacturing hubs, progressive regulatory harmonization efforts, and variable market access conditions. European markets often lead in specialized contract manufacturing capacity, with a strong emphasis on high-quality GMP operations and an entrenched supplier base for analytical and downstream services. Meanwhile, pockets across the Middle East and Africa are attracting investment through incentive programs aimed at localizing biologics production, although infrastructure and skilled workforce development remain uneven.

Asia-Pacific has emerged as a pivotal region for capacity expansion, driven by rapidly growing domestic demand, competitive manufacturing costs, and government policies that encourage biomanufacturing investments. Markets across this region demonstrate significant capability in fill-finish and upstream operations, with an accelerating focus on higher-complexity modalities. Cross-regional partnerships and technology transfer initiatives are commonplace as companies seek to balance cost, scale, and access to regional markets, making Asia-Pacific a central node in global outsourcing strategies.

Evidence-based corporate strategic patterns revealing how leading providers are aligning capacity, specialization, digital investment, and partnership models to win in biologics outsourcing

Leading companies in the biologics outsourcing ecosystem are pursuing differentiated strategies that balance capacity expansion, technical specialization, and commercial partnerships to capture emerging opportunity. Some providers are concentrating on vertical integration, building capabilities that span analytical development through commercial fill-finish to offer end-to-end solutions that reduce handoffs and speed time to market. Others are specializing in niche areas such as viral vector production, high-throughput analytics, or continuous downstream processing to serve high-complexity programs where deep expertise and validated processes command premium positioning.

Mergers and strategic alliances remain key vectors for capability acquisition, allowing organizations to combine complementary strengths, enter new geographic markets, and accelerate service portfolios without the lead time required for organic expansion. Investment in digital twins, process analytical technology, and real-time monitoring is also a common theme, as companies seek to improve tech transfer success rates, reduce batch failures, and provide clients with transparent process data. In parallel, firms are sharpening commercial models to include risk-sharing elements, capacity reservations, and flexible pricing that align provider incentives with client program milestones.

Talent and quality systems continue to differentiate performance. Providers that demonstrate rigorous regulatory compliance, experienced clinical and technical teams, and scalable quality management frameworks are more successful in securing long-term partnerships. In sum, company strategies are evolving to emphasize resilience, deep technical differentiation, and client co-development as the primary drivers of sustainable growth.

Practical and prioritized actions for executives to fortify supply chains, accelerate tech transfer, and invest in capabilities that deliver measurable resilience and competitive advantage

Industry leaders should adopt a pragmatic and forward-looking set of actions to strengthen competitive position and operational resilience. First, map supply chains with granularity to identify single points of failure, tariff exposure, and critical lead-time dependencies, then implement tiered mitigation plans that combine strategic inventory, supplier diversification, and qualification pathways for alternate components. Second, prioritize investments in modular and single-use technologies where program flexibility yields measurable benefits, while maintaining selective stainless steel capabilities for high-volume, cost-effective production.

Third, deepen regulatory engagement early in development programs to accelerate approvals and reduce rework cycles; proactively align analytical strategies with regulatory expectations and invest in robust comparability datasets for process changes. Fourth, formalize partnerships that integrate development and manufacturing workflows, enabling smoother tech transfers and shared accountability for timelines and quality outcomes. Fifth, expand digital and analytics capabilities to enable real-time process monitoring, predictive maintenance, and enhanced process characterization, thereby reducing operational variability and improving yield.

Finally, build human capital pipelines through targeted training and cross-functional teams that blend scientific, regulatory, and supply chain expertise. By executing these actions in concert-balancing near-term risk mitigation with longer-term capability development-organizations can secure competitive advantage in a market that prizes speed, quality, and adaptability.

Transparent mixed-methods research approach integrating primary interviews, secondary evidence, segmentation mapping, and scenario analysis to produce actionable insights

This research leveraged a mixed-methods approach to ensure robustness and practical relevance. Primary research included structured interviews with executives and technical leaders from development and manufacturing organizations, complemented by consultations with regulatory experts and supply chain specialists to validate assumptions and capture real-world decision heuristics. These primary inputs were triangulated with targeted secondary research drawn from scientific literature, regulatory guidance documents, industry whitepapers, and validated public disclosures to build a comprehensive evidentiary base.

Analytical methods incorporated segmentation mapping to align capability requirements with therapeutic modality and process stage, as well as scenario analysis to explore the implications of trade policy changes, capacity constraints, and technology adoption pathways. Data synthesis emphasized reproducibility and transparency: methodological choices, inclusion criteria for primary sources, and validation steps were documented to enable auditability. Throughout, the research team applied conservative inference rules, avoided extrapolating beyond available evidence, and prioritized corroborated insights over speculative claims.

Limitations were acknowledged and addressed through sensitivity testing and by flagging areas of higher uncertainty where emerging technologies or policy shifts could materially change trajectories. The resulting methodology balances depth of technical insight with pragmatic applicability, producing findings designed to inform strategic planning and operational decision-making for stakeholders across the outsourcing continuum.

A concise synthesis that underscores the strategic imperatives for buyers and providers to align capabilities, governance, and investments for sustainable biologics development

The trajectory of biologics outsourcing reflects a sector in strategic transition: technological innovation, regulatory evolution, and supply chain realignment are collectively raising the bar for partner selection and program execution. Organizations that proactively reconfigure sourcing strategies, invest in targeted capabilities, and cultivate data-driven decision frameworks will be best positioned to translate scientific advances into reliable, scalable therapies. At the same time, trade policy developments and regional investment shifts underscore the need for agile supply chain architectures and informed scenario planning.

Success in this environment requires integrated thinking across scientific, operational, and commercial domains. Providers that combine deep technical expertise with transparent quality systems and flexible commercial models will capture comparative advantage, while buyers that partner strategically and share risks can accelerate time to clinic and market. Ultimately, the biologics outsourcing landscape rewards those who treat external partners as co-innovators and who invest in the governance, talent, and digital infrastructure necessary to sustain complex programs across the product lifecycle.

In closing, the imperative is clear: align outsourcing decisions with long-term strategic objectives, continuously reassess supplier and regional risk, and prioritize investments that deliver both immediate operational benefits and enduring capability uplift.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid expansion of mRNA-focused CDMO capacity to accommodate global vaccine production demands
  • 5.2. Rising adoption of single-use bioreactor technologies to accelerate bioprocessing flexibility and efficiency
  • 5.3. Strategic partnerships between biotech firms and CDMOs for advanced gene therapy development pipelines
  • 5.4. Integration of digital quality management systems to ensure real-time compliance and process transparency
  • 5.5. Increased investment in flexible manufacturing lines for personalized cell and gene therapy products
  • 5.6. Emphasis on sustainable outsourcing practices to reduce carbon footprint in biologics manufacturing supply chains
  • 5.7. Growing trend of regional nearshoring strategies to mitigate supply chain disruptions and geopolitical risks
  • 5.8. Incorporation of artificial intelligence and machine learning in process development for biologics optimization

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biologics Outsourcing Market, by Service Type

  • 8.1. Analytical Services
  • 8.2. Development
  • 8.3. Fill Finish
  • 8.4. Manufacturing
    • 8.4.1. Downstream
      • 8.4.1.1. Chromatography
      • 8.4.1.2. Filtration
    • 8.4.2. Upstream
      • 8.4.2.1. Single Use
      • 8.4.2.2. Stainless Steel

9. Biologics Outsourcing Market, by Therapeutic Area

  • 9.1. Cell Therapy
    • 9.1.1. Allogeneic
    • 9.1.2. Autologous
  • 9.2. Gene Therapy
    • 9.2.1. Non Viral
    • 9.2.2. Viral Vector
  • 9.3. Monoclonal Antibodies
  • 9.4. Vaccines
    • 9.4.1. Prophylactic
      • 9.4.1.1. Bacterial
      • 9.4.1.2. Viral
    • 9.4.2. Therapeutic

10. Biologics Outsourcing Market, by Process Stage

  • 10.1. Clinical
    • 10.1.1. Phase I
    • 10.1.2. Phase II
    • 10.1.3. Phase III
  • 10.2. Commercial
  • 10.3. Research

11. Biologics Outsourcing Market, by Outsourcing Model

  • 11.1. CDMO
  • 11.2. CMO
  • 11.3. CRO

12. Biologics Outsourcing Market, by End User

  • 12.1. Biotech Companies
  • 12.2. Pharmaceutical Companies
  • 12.3. Research Institutes

13. Biologics Outsourcing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Biologics Outsourcing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Biologics Outsourcing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Thermo Fisher Scientific Inc.
    • 16.3.2. Catalent, Inc.
    • 16.3.3. Lonza Group AG
    • 16.3.4. Samsung Biologics Co., Ltd.
    • 16.3.5. Boehringer Ingelheim International GmbH
    • 16.3.6. Fujifilm Diosynth Biotechnologies UK Ltd
    • 16.3.7. AGC Biologics Inc.
    • 16.3.8. WuXi Biologics (Cayman) Inc.
    • 16.3.9. Recipharm AB
    • 16.3.10. Vetter Pharma-Fertigung GmbH & Co. KG

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PROCESS STAGE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PROCESS STAGE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY OUTSOURCING MODEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY OUTSOURCING MODEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BIOLOGICS OUTSOURCING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. BIOLOGICS OUTSOURCING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BIOLOGICS OUTSOURCING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY ANALYTICAL SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY ANALYTICAL SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY ANALYTICAL SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY ANALYTICAL SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY ANALYTICAL SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY ANALYTICAL SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY FILL FINISH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY FILL FINISH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY FILL FINISH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY FILL FINISH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY FILL FINISH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY FILL FINISH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY MANUFACTURING, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY MANUFACTURING, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY MANUFACTURING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY MANUFACTURING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY MANUFACTURING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY MANUFACTURING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY MANUFACTURING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY MANUFACTURING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY DOWNSTREAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY DOWNSTREAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY DOWNSTREAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY DOWNSTREAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY DOWNSTREAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY DOWNSTREAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CHROMATOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CHROMATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CHROMATOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CHROMATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CHROMATOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY FILTRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY FILTRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY FILTRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY FILTRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY FILTRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY FILTRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY UPSTREAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY UPSTREAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY UPSTREAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY UPSTREAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY UPSTREAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY UPSTREAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY SINGLE USE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY SINGLE USE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY SINGLE USE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY SINGLE USE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY SINGLE USE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY SINGLE USE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY STAINLESS STEEL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY STAINLESS STEEL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY STAINLESS STEEL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY STAINLESS STEEL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY STAINLESS STEEL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY STAINLESS STEEL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CELL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY ALLOGENEIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY ALLOGENEIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY ALLOGENEIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY ALLOGENEIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY ALLOGENEIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY ALLOGENEIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY AUTOLOGOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY AUTOLOGOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY AUTOLOGOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY AUTOLOGOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY GENE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY NON VIRAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY NON VIRAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY NON VIRAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY NON VIRAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY NON VIRAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY NON VIRAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY VACCINES, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PROPHYLACTIC, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PROPHYLACTIC, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PROPHYLACTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PROPHYLACTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PROPHYLACTIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PROPHYLACTIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PROPHYLACTIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PROPHYLACTIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY BACTERIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY BACTERIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY BACTERIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY VIRAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY VIRAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY VIRAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY VIRAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY VIRAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY VIRAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PROCESS STAGE, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PROCESS STAGE, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CLINICAL, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CLINICAL, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CLINICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CLINICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CLINICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CLINICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CLINICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CLINICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PHASE I, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PHASE I, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PHASE I, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PHASE I, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PHASE I, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PHASE II, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PHASE II, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PHASE II, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PHASE II, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PHASE II, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PHASE III, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PHASE III, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PHASE III, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PHASE III, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PHASE III, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY COMMERCIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY COMMERCIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY COMMERCIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY COMMERCIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY COMMERCIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY OUTSOURCING MODEL, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY OUTSOURCING MODEL, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CDMO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CDMO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CDMO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CDMO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CDMO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CDMO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CMO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CMO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CMO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CMO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CMO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CMO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CRO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CRO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CRO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CRO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CRO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CRO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY BIOTECH COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY BIOTECH COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY BIOTECH COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY BIOTECH COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY BIOTECH COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY BIOTECH COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY MANUFACTURING, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY MANUFACTURING, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY CELL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY VACCINES, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY PROPHYLACTIC, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY PROPHYLACTIC, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY PROCESS STAGE, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY PROCESS STAGE, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY CLINICAL, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY CLINICAL, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY OUTSOURCING MODEL, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY OUTSOURCING MODEL, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. NORTH AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY MANUFACTURING, 2018-2024 (USD MILLION)
  • TABLE 270. NORTH AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY MANUFACTURING, 2025-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 272. NORTH AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 275. NORTH AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 276. NORTH AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 277. NORTH AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 278. NORTH AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY CELL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 279. NORTH AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 280. NORTH AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 281. NORTH AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 282. NORTH AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY VACCINES, 2025-2032 (USD MILLION)
  • TABLE 283. NORTH AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY PROPHYLACTIC, 2018-2024 (USD MILLION)
  • TABLE 284. NORTH AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY PROPHYLACTIC, 2025-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY PROCESS STAGE, 2018-2024 (USD MILLION)
  • TABLE 286. NORTH AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY PROCESS STAGE, 2025-2032 (USD MILLION)
  • TABLE 287. NORTH AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY CLINICAL, 2018-2024 (USD MILLION)
  • TABLE 288. NORTH AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY CLINICAL, 2025-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY OUTSOURCING MODEL, 2018-2024 (USD MILLION)
  • TABLE 290. NORTH AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY OUTSOURCING MODEL, 2025-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. NORTH AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. LATIN AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. LATIN AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. LATIN AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. LATIN AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 297. LATIN AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY MANUFACTURING, 2018-2024 (USD MILLION)
  • TABLE 298. LATIN AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY MANUFACTURING, 2025-2032 (USD MILLION)
  • TABLE 299. LATIN AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 300. LATIN AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 301. LATIN AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 302. LATIN AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 303. LATIN AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 304. LATIN AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 305. LATIN AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 306. LATIN AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY CELL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 307. LATIN AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 308. LATIN AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 309. LATIN AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 310. LATIN AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY VACCINES, 2025-2032 (USD MILLION)
  • TABLE 311. LATIN AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY PROPHYLACTIC, 2018-2024 (USD MILLION)
  • TABLE 312. LATIN AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY PROPHYLACTIC, 2025-2032 (USD MILLION)
  • TABLE 313. LATIN AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY PROCESS STAGE, 2018-2024 (USD MILLION)
  • TABLE 314. LATIN AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY PROCESS STAGE, 2025-2032 (USD MILLION)
  • TABLE 315. LATIN AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY CLINICAL, 2018-2024 (USD MILLION)
  • TABLE 316. LATIN AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY CLINICAL, 2025-2032 (USD MILLION)
  • TABLE 317. LATIN AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY OUTSOURCING MODEL, 2018-2024 (USD MILLION)
  • TABLE 318. LATIN AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY OUTSOURCING MODEL, 2025-2032 (USD MILLION)
  • TABLE 319. LATIN AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 320. LATIN AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 321. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 322. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 323. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 324. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 325. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTS